• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Krystexxa (pegloticase)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Krystexxa (pegloticase)

  • Profile

Profile

Contact Information

Contact: Horizon Therapeutics
Website: https://www.krystexxa.com/

Currently Enrolling Trials

    Show More

    General Information

    Krystexxa is a uric acid specific enzyme, a recombinant uricase, achieves its therapeutic effect by catalyzing the oxidation of uric acid to allantoin, thereby lowering serum uric acid. Allantoin is an inert and water-soluble purine metabolite. It is readily eliminated, primarily by renal excretion.

    Krystexxa is specifically indicated for the treatment of chronic gout in adult patients refractory to conventional therapy.

    Mechanism of Action

    Krystexxa is a uric acid specific enzyme, which is a PEGylated product that consists of recombinant modified mammalian urate oxidase (uricase) produced by a genetically modified strain of Escherichia coli. It achieves its therapeutic effect by catalyzing the oxidation of uric acid to allantoin, thereby lowering serum uric acid. Allantoin is an inert and water-soluble purine metabolite. It is readily eliminated, primarily by renal excretion.

    Side Effects

    Adverse events associated with the use of Krystexxa may include, but are not limited to, the following:

    • Gout flares
    • Infusion reactions
    • Nausea
    • Contusion or ecchymosis
    • Nasopharyngitis
    • Constipation
    • Chest pain
    • Anaphylaxis
    • Vomiting

    Dosing/Administration

    Krystexxa is supplied as a solution intended for intravenous infusion after dilution. The recommended initial dose is 8mg (uricase protein) given as an intravenous infusion every two weeks.

    Clinical Trial Results

    FDA approval of Kyrstexxa was based on two replicate, multicenter, randomized, double-blind, placebo-controlled studies of six months duration: trial one and trial two. The trials enrolled adult patients with chronic gout refractory to conventional therapy, who were randomized to receive Krystexxa 8 mg every two weeks or every four weeks or placebo. The studies were stratified for the presence of tophi: 71 percent of patients had baseline tophi. The primary endpoint in both trials was the proportion of patients who achieved plasma uric acid (PUA) less than 6 mg/dL for at least 80 percebt of the time during month three and month six. Data showed that a greater proportion of patients treated with Krystexxa every two weeks achieved urate lowering to below 6 mg/dL than patients receiving placebo. Although the four week regimen also demonstrated efficacy for the primary endpoint, this regimen was associated with increased frequency of anaphylaxis and infusion reactions and less efficacy with respect to tophi.

    Trial One
    Pegloticase 8 mg every two weeks: 47 percent responders; Pegloticase 8 mg every four weeks: 20 percent responders and placebo: zero percent responders.

    Trial Two
    Pegloticase 8 mg every twp weeks: 38 percent responders; Pegloticase 8 mg every four weeks: 49 percent responders and placebo zero percent responders.

    The effect of treatment on tophi was a secondary efficacy endpoint. A pooled analysis was conducted. At month six, the percentage of patients who achieved a complete response (defined as 100 percent resolution of at least one target tophus, no new tophi and no single tophus showing progression) was 45 percent, 26 percent and 8 percent, with Krystexxa 8 mg every two weeks, Krystexxa 8 mg every four weeks and placebo, respectively. The difference between Krystexxa and placebo was statistically significant for the every-two-week dosing regimen, but not for the every-four-week dosing regimen.

    Additional Information

    For additional information regarding Krystexxa or gout, please visit the Krystexxa web page.

    Approval Date: 2010-09-01
    Company Name: Savient Pharma
    Back to Listings

    Upcoming Events

    • 28Jun

      Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

    • 16Oct

      WCG MAGI's Clinical Research Hybrid Conference - 2022 West

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • Protocol-360x240.png

      Avoid Deviations by Making Protocol Review a Team Effort

    • SelectionProcess-360x240.png

      Give Us a Voice: Sites Clamor for a Say on Vendor Selection

    • Convince-360x240.png

      Use Data and Details to Convince Site Leadership to Add Staff

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing